This creates a four-pathway research compound targeting GLP-1, GIP, glucagon, and amylin receptors
While weight loss benefits those with obesity, excessive loss may signal underlying pathology rather than the GLP-1 RAs effect
Fatigue and decreased energy levels affect some users, particularly during the first few weeks
Severe or persistent vomiting Signs of dehydration (excessive thirst, dark urine, dizziness) Severe abdominal pain Any symptoms of pancreatitis (pain radiating to your back, fever) Significant changes in bowel habits lasting more than a few days GLP-1 Medications in 2026: Whats New The GLP-1 landscape has expanded significantly entering 2026, offering patients more options and broader access than ever before
Silva specializes in evidence-based weight management, including GLP-1 and GIP therapies such as semaglutide and tirzepatide
A triple agonist activates three different receptors simultaneously